Physician profile
Robin Blum
NPI 1083823363
$12,269.09
in general payments reported to CMS, 2019-2025
37 companies · $2,223 in 2025
The $2,223 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $1,033 · 2021: $2,338 · 2022: $1,192 · 2023: $1,763 · 2024: $2,048 · 2025: $2,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,874 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,873.55 |
| Education | $160.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,638.65 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,423.16 | 2019-2025 | Skyrizi, Botox |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,367.86 | 2019-2025 | Cabtreo, Jublia |
| Incyte Corporation | $857.73 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $832.55 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $662.63 | 2019-2025 | |
| Amgen INC. | $569.41 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $551.47 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $536.92 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $431.33 | 2022-2025 | Bimzelx, Cimzia |
| Allergan, INC. | $399.54 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $380.24 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $340.92 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $321.04 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $229.91 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $213.62 | 2019-2025 | |
| Celgene Corporation | $159.81 | 2019 | |
| Dermavant Sciences, INC. | $153.96 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $107.74 | 2024-2025 | Zoryve |
| Glenmark Therapeutics INC. | $101.00 | 2019 | |
| Merz North America, INC. | $100.03 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $98.85 | 2023-2024 | Ycanth |
| Journey Medical Corporation | $97.53 | 2020-2025 | |
| Almirall LLC | $92.50 | 2019-2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $90.61 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $80.09 | 2023-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Dermira, INC. | $69.04 | 2020-2021 | |
| Botanix Sb INC | $55.33 | 2025 | Sofdra |
| Organon LLC | $49.14 | 2025 | |
| Stemline Therapeutics INC. | $44.75 | 2021 | |
| Taro Pharmaceuticals USA, INC. | $39.59 | 2019 | |
| Cipher Pharmaceuticals US LLC | $24.21 | 2025 | Natroba, Spinosad |
| Sebela Pharmaceuticals INC. | $21.45 | 2019 | |
| Encore Dermatology INC. | $21.27 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.79 | 2019 | |
| Medline Industries LP | $16.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.